TapImmune Inc. is a biotechnology company specializing in the development of innovative therapeutics and vaccines in the areas of oncology and infectious disease. The company’s TAP (transporters associated with antigen processing) technology has been featured in media outlets such ABC News, Business Week and Popular Mechanics as well as in many respected medical journals such as the Journal of Immunology.

The company’s lead product, the TAP vaccine, performs a key step in moving characteristic markers called antigens to the surfaces of cells. Without TAP – there are no cancer markers – so the body’s immune system fails to spot the rogue cells and the cancerous cells can grow undetected. TapImmune’s vaccine has shown effective restoration of TAP which restores and augments the marker (antigen) presentation and subsequent recognition and killing of cancer cells by the immune system.

The TAP molecule also works as an adjuvant to enhance targeted vaccines against infectious diseases. For example, including TAP in the studied smallpox vaccine showed potency was increased by 100 to 1,000 times.

TapImmune realizes that the potential for the global vaccine market is huge – a $21 billion market in 2010. The company’s strategy is to build a patented proprietary product pipeline through conducting pre-clinical vaccine programs and then moving successes on to human trials. Then the company will capitalize on the breadth of the TAP technology through collaborative partnerships and license agreements globally.

Let us hear your thoughts: TapImmune, Inc. Message Board